Actualités Gilead Sciences
The joke cryptocurrency Dogecoin (DOGE) touched a fresh all-time high in the early hours of Wednesday, crossing the much sought-after 69 cent mark. What Happened: DOGE touched $0.6953 minutes before press time. The meme cryptocurrency now has a market capitalization of $89.70 billion, which it puts ahead of Snap Inc (NYSE: SNAP ), which has a valuation of $84.98 billion and General Motors Company (NYSE: GM ), which has a market cap of $80.24 billion. See Also: How to Buy Dogecoin (DOGE) Gilead Sciences, Inc (NASDAQ: GILD ) and FedEx Corporation (NYSE: FDX ) are some other large companies that are trailing the Shiba Inu-themed coin in terms of … Full story available on Benzinga.com
A biotech VC accuses his Proskauer lawyers of bungling a hedge fund deal, costing him 'hundreds of millions'04 May, 17:15, Business Insider • Développer
Summary List Placement A life sciences venture capitalist claims he was shut out of the meteoric rise of his former partner's hedge fund because his ex-lawyers at Proskauer Rose bungled the deal. Dr. Robert Adelman, the managing partner of venBio, says he missed out on the success of Avoro Capital, a hedge fund spun out of venBio in 2016. Lawyers at Proskauer made a drafting error in fund documents that forced him to sell his Avoro stake in 2019, Adelman alleges. His state-court lawsuit against the Big Law firm hasn't previously been reported. Avoro was up 19.5% for the year through last August and grew 60% in 2019, the year Adelman was pushed out, according to Institutional Investor . One of its top holdings was Immunomedics Inc., which was purchased by Gilead Sciences last year for $21 billion, generating huge profits for Avoro. Proskauer's terms gave Behzad Aghazadeh, the hedge fund's managing partner, the authority to declare a "strategic transaction" that would result in the redemption of Adelman's 27.5% stake in the fund, according to the March 2020 lawsuit.
Gilead Sciences Inc (NASDAQ: GILD ) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but higher than $1.68 last year. Sales of $6.42 billion missed the consensus of $6.74 billion but grew 16% Y/Y. Revenue … Full story available on Benzinga.com
As Indian authorities and hospitals struggle to cope with record Covid-19 infections and deaths, companies ranging from the nation’s biggest conglomerate to global giants like Amazon.com Inc. are stepping in to help ease the crisis.Reliance Industries Ltd., controlled by Asia’s richest man Mukesh Ambani, the Tata group, global drug giants like Gilead Sciences Inc., technology titans such as Alphabet Inc. are all rushing in supplies and funds. Blackstone Group Inc.’s Chairman Stephen Schwarzman said his private equity firm is committing $5 million to support India’s Covid relief and vaccination services to “marginalized communities.”With haunting visuals of mass funeral pyres, long lines of ambulances outside overcrowded hospitals, and desperate pleas on social media for oxygen canisters, the unfolding tragedy is prompting some of the biggest corporations to organize aid for a country they view as a crucial market with 1.3 billion consumers. India’s central and state governments, grossly unprepared to tackle the latest coronavirus wave, have also encouraged the non-state sector to help narrow the vast chasm of shortages.Most critical has been the unavailability of medical oxygen, and a bulk of the efforts have been directed at boosting supplies.
On Tuesday night, Handmaid's Tale fans were able to return to Gilead a day earlier than expected when Hulu surprise-dropped the first three episodes of the show's fourth season, which had been scheduled to debut on April 28. The surprise drop began with a Facebook Premiere video on Tuesday night, which notified The Handmaid's Tale's…
A chemist by training, he turned Gilead Sciences into a leading, and lucrative, innovator with single-pill treatments for H.I.V. and hepatitis C.
The company, which has development programs for conditions including hepatitis B, prostate cancer and non-small cell lung cancer, has raised $216 million to date from Gilead Sciences , Sequoia Capital China and Oxford Sciences Innovation among others.
A government order banning all exports of the drug remdesivir and its active pharmaceutical ingredients has landed exporters in a fix.Any duty-free import allowed under advance licence has to be matched with exports, but exporters manufacturing remdesivir have been barred from exporting the drug following the government order. They are also not allowed to sell in the domestic market due to the advance licence condition.The apex pharma exporters body has raised an alarm on the issue and sought urgent government intervention.Referring to the government directive to ban exports of remdesivir, active pharmaceutical ingredients (APIs) and formulation on April 11 amid an acute shortage of the drug used in the treatment of Covid-19, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) has said the notification is causing hardships as companies import API against advance licence which can be utilised for export of formulation and is not for domestic sale.“Under no circumstances, companies can divert their production of remdesivir finished formulation for domestic purposes, as per the undertaking given at the time of applying for advance licence and the condition of the licence,” the council said in its representation to the commerce and industry ministry.82247785Under an advance licence, duty-free imports are bound to certain export obligations.The council said customs and drug authorities have stopped the clearance of export consignments.The government, meanwhile, has waived customs duty on the drug and its API till October 31, a move aimed at boosting the availability of the anti-viral drug amid a surge in Covid-19 cases in the country.India has also exempted from customs duty the import of beta cyclodextrin which is used in the manufacture of remdesivir.
Kite's YESCARTA® (Axicabtagene Ciloleucel) Reimbursed in Alberta for the Treatment of Certain Types of Aggressive Non-Hodgkin Lymphoma23 Apr, 18:00, Benzinga • Développer
-- YESCARTA is a Chimeric Antigen Receptor T-Cell (CAR T) Therapy -- -- CAR T Therapy is a Hematologic Cancer Treatment in Which a Patient's Own T Cells are Engineered to Seek and Destroy Cancer Cells -- -- CAR T Therapy is Manufactured Specifically for Each Individual Patient -- MISSISSAUGA, ON , April 23, 2021 /CNW/ - Gilead Sciences Canada, Inc. ( Gilead Canada ) announced today that YESCARTA ® (axicabtagene ciloleucel) is now available in Alberta as a treatment for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. i YESCARTA will be manufactured by Kite, a Gilead Company (Kite) at its commercial manufacturing facility in El Segundo, California . YESCARTA is a chimeric antigen receptor T-cell (CAR T) therapy, an individualized method of treatment that harnesses the power of the body's own immune system to target cancer cells.
Drug firm Cipla said it has increased the production of COVID-19 drug remdesivir two-fold since the last wave of the pandemic.In view of increased demand for the drug due to a surge in COVID-19 cases, the Centre on Sunday prohibited the exports of remdesivir injection and its active pharmaceutical ingredients (API) till the situation improves."We have scaled up the production of remdesivir by 2x from the last wave of the pandemic. Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network, to service the demand," Cipla said in a statement.Seven Indian companies are producing the injection under voluntary licensing agreement with Gilead Sciences, USA. They have an installed capacity of about 38.80 lakh units per month, the Ministry of Health and Family Welfare had said on Sunday.The Department of Pharmaceuticals has been in contact with the domestic manufacturers to ramp up the production of remdesivir, it added. Cipla also said given the spike in cases and surge in demand, it is facing a shortage of another drug Tocilizumab and is working closely with its partner in taking necessary steps to ensure its availability.
India's Cipla Ltd has doubled production of COVID-19 medication remdesivir to help meet "unprecedented demand" as the country battles a massive second wave of infections, the drugmaker said on Tuesday. India has overtaken Brazil as the world's second-worst coronavirus-hit country after the United States, having administered about 107 million vaccine doses among a population of 1.4 billion. On Sunday, the country banned the export of anti-viral drug remdesivir and its active pharmaceutical ingredients to deal with crippling shortages of the medication in many parts. "We have scaled up the production of remdesivir by 2x from the last wave of the pandemic," Cipla said in a statement. "Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network." The company is working with authorities to restrict remdesivir supply just to hospitals and places with a high burden of severe COVID-19 cases, it added. Just two months ago, Cipla had projected falling demand for remdesivir in India as coronavirus infections were on a steady decline.
RBC Capital Stick to Their Buy Rating for Gilead Sciences
The Centre today banned export of the anti-viral drug Remdesivir amid a surge in coronavirus cases in the country. In an order, the government said it has banned export of Remdesivir injection and Remdesivir active pharmaceutical ingredients (API) till the pandemic situation in the country stabilises."India is witnessing a recent surge in COVID cases. As on 11.04.2021, there are 11.08 lakh active COVID cases and they are steadily increasing. This has led to a sudden spike in demand for Injection Remdesivir used in treatment of COVID patients. There is a potential of further increase in this demand in the coming days" read the order.In addition to the ban on exports, the government has also taken a few steps to ensure easy access of hospital and patients to Remdesivir. These steps are:- All domestic manufactures of Remdesivir have been advised to display on their website, details of their stockists/distributors to facilitate access to the drug.- Drugs inspectors and other officers have been directed to verify stocks and check their malpractices and also take other effective actions to curb hoarding and black marketing.
- ← précédent
- suivant →